



June 14, 2016

## **Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference**

WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- [Syndax Pharmaceuticals, Inc.](http://www.syndax.com) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination therapy across multiple cancer indications, today announced that President and Chief Operating Officer, Michael A. Metzger, will present at the JMP Securities Life Sciences Conference on June 22, 2016 at 12:30 p.m. EDT at the St. Regis Hotel in New York City.

A live webcast of the Company's presentation can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the event will also be available for a limited time.

### **About Syndax Pharmaceuticals, Inc.**

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Entinostat, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer. Concurrently, Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer. For more information on Syndax please visit [www.syndax.com](http://www.syndax.com).

Investor and Media Contacts

Barbara Ryan  
[bryan@syndax.com](mailto:bryan@syndax.com)  
(646) 690-7639